- Brian Wong, M.D., Ph.D. — Chief Executive Officer
- William Ho, M.D., Ph.D. — Chief Medical Officer
- Dirk Brockstedt, Ph.D. — Senior Vice President, Biology
- Paul Kassner, Ph.D. — Vice President, Quantitative Biology
- David Wustrow Ph.D. — Senior Vice President, Drug Discovery
Brian Wong, M.D., Ph.D.
Chief Executive Officer
Brian joined FLX Bio in 2015, bringing more than 15 years of experience leading research organizations. Most recently, he served as Senior Vice President, Research, and Head of Immuno-Oncology at Five Prime Therapeutics, where he led the discovery of novel immuno-oncology therapeutics, one of which has progressed into clinical trials in combination with Bristol-Myers Squibb Co.’s (BMS) Opdivo™. BMS has pledged more than $1 billion to exclusively license the program.
Prior to Five Prime, Brian served as Director of Research in the Inflammation Disease Biology Area at Roche Palo Alto from 2005 to 2009. He led the development of Roche’s rheumatology discovery portfolio, consisting of more than 20 biologics and small-molecule programs in clinical phases from discovery to mid-stage development. From 2000 to 2005, he held various leadership roles at Rigel Pharmaceuticals, where he identified and developed clinical candidates for allergic, autoimmune and respiratory disorders.
Brian received his M.D. from the Weill Cornell Medical College and his Ph.D. in Immunology from Rockefeller University under Dr. Yongwon Choi, Ph.D., a Howard Hughes Medical Institute Investigator, and in collaboration with Nobel Laureate Dr. Ralph Steinman, M.D.
William Ho, M.D., Ph.D.
Chief Medical Officer
Bill became FLX Bio’s Chief Medical Officer in 2015, bringing with him extensive experience both in clinical immunotherapy and in the translational and clinical development of novel therapeutics to treat cancer. He joined FLX Bio after serving as the Vice President of Clinical Development at Igenica Biotherapeutics where he led the clinical development of antibody-based therapeutics. Prior to Igenica, Bill served as a Senior Medical Director in the Exploratory Clinical Development (BioOncology) group at Genentech, where for seven years he led the development of multiple small molecule, antibody, and antibody-drug conjugate programs from IND filing to Phase III, including clinical development of Gazyva® (obinutuzumab) and Venclexta™ (venetoclax).
Bill received his A.B. in Molecular Biology from Princeton University and both his M.D. and his Ph.D. in Microbiology and Immunology from the Stanford University School of Medicine, where he studied cellular immunology in the laboratory of Mark Davis, Ph.D. Bill completed his internship and residency in Internal Medicine at the University of California, San Francisco, and received his training in Medical Oncology at the University of Washington and Fred Hutchinson Cancer Research Center, where he studied adoptive immunotherapy methods to treat leukemia.
Dirk Brockstedt, Ph.D.
Senior Vice President, Biology
Dirk joined FLX Bio in January 2018, bringing a wealth of experience in immuno-oncology at all stages of discovery, translational and clinical development, as well as a deep knowledge of immunology and the tumor microenvironment. He joined FLX Bio from Aduro Biotech, where he served as Executive Vice President of Research and Development. Prior to Aduro, Dirk held positions of increasing responsibility within the immunology department of Cerus Corporation most recently serving as Director of Immunology. Prior to Cerus, he served as a scientist at Aventis in the immunotherapy and anti-angiogenesis group, developing novel therapies against cancer.
Dirk holds an M.S. in Microbiology from the University of Kiel and he earned his Ph.D. from the University of Kiel and Stanford University. He was a post-doctoral fellow at the Stanford School of Medicine in the Department of Pathology. He has co-authored 40 scientific papers and is a named inventor on seven issued patents and several pending applications.
Paul Kassner, Ph.D.
Vice President, Quantitative Biology
Paul joined FLX Bio in 2016, bringing more than 15 years of experience building and leading high performance technical groups in various biopharmaceutical organizations. Most recently, Paul was Director of Research and Head of the Genome Analysis Unit at Amgen, Inc. During his eleven years at Amgen, he developed and implemented multiple high-throughput platforms for drug discovery and target identification across a broad spectrum of therapeutic areas. Prior to Amgen, Paul held scientific and leadership positions in several smaller companies which enabled him to exercise his passion for creating novel technology platforms to enable drug discovery.
Paul received his B.S. in Genetics and Development from the University of Illinois at Champaign-Urbana before performing graduate research at the Dana-Farber Cancer Institute and earning his Ph.D. in Immunology from Harvard University. Paul completed postdoctoral work in Cellular Neuroscience at the University of California, San Diego.
David Wustrow Ph.D.
Senior Vice President, Drug Discovery
David joined FLX Bio in 2016, bringing more than 20 years of experience in drug discovery. Most recently, David served as Vice President, Chemical and Pharmaceutical Sciences at Cleave Biosciences where he led chemistry efforts directed towards the discovery and development of first-in-class drug products for solid and hematologic malignancies. Previously, he held several escalating positions at biotechnology and pharmaceutical companies including Vice President, Medicinal Chemistry and Executive Director of Scientific Assessment and Licensing at XenoPort, Executive Director of Chemistry at Neurogen, and Senior Director of Neuroscience Chemistry at Pfizer, where he led cross-functional teams to deliver preclinical development candidates for the treatment of pain, inflammation and psychiatric disorders.
David received his B.S. from Pennsylvania State University and holds a Ph.D. in Organic Synthesis from The University of Rochester. He is the author of over 40 peer-previewed publications and an inventor on over 30 U.S. patents.